Infinity pharmaceuticals, inc. (INFI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Collaboration revenue

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenues:
Total revenues

1,335

3,049

2,888

24,545

24,288

22,146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

6,000

-

-

-

18,723

27,803

118,546

113,959

109,066

104,342

174,238

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaborative research and development revenue from Purdue entities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69,438

92,742

90,788

92,773

92,944

88,334

0

0

0

Operating expenses:
Research and development

28,696

27,116

23,637

21,940

19,613

19,758

18,591

22,550

22,702

20,830

31,940

35,416

84,462

119,611

143,839

168,754

149,869

199,109

196,301

203,467

197,570

143,633

134,143

116,105

114,020

99,760

113,185

107,823

110,275

118,595

108,471

116,394

112,855

108,582

117,420

107,013

0

0

0

General and administrative

14,215

14,289

14,624

14,425

14,040

14,248

14,902

15,965

18,784

21,615

25,718

28,333

37,820

42,219

42,999

45,633

39,351

37,065

35,096

33,384

31,031

29,285

28,395

27,672

27,290

27,916

28,534

27,509

28,500

27,882

26,815

25,991

24,655

22,719

21,690

21,437

0

0

0

Royalty expense

805

7,308

7,192

6,985

6,830

69

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

43,716

48,713

45,453

43,350

40,483

34,075

33,493

38,515

41,486

42,445

57,658

63,749

122,282

161,830

186,838

214,387

189,220

236,174

231,397

236,851

228,601

172,918

162,538

143,777

141,310

127,676

141,719

135,332

138,775

146,477

135,286

142,385

137,510

131,301

139,111

128,451

0

0

0

Gain on AbbVie Opt-Out (note 11)

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on termination of Purdue entities alliance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Loss from operations

-42,381

-45,664

-42,565

-18,805

-16,195

-11,929

-11,493

-32,515

-35,486

-36,445

-51,658

-63,749

-599

-30,891

-46,819

16,375

-75,261

-127,108

-127,055

-62,613

-59,243

-7,923

-1,899

-143,777

-141,310

-127,676

-141,718

-88,776

-70,308

-52,808

-19,294

-49,643

-46,722

-38,528

-46,167

-40,117

0

0

0

Other income (expense):
Income from Massachusetts tax incentive award

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

Investment and other income

0

-

1,142

1,045

0

-

657

1,481

1,643

1,787

2,270

1,985

1,905

2,015

1,545

879

888

435

281

258

131

339

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense (note 9)

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Related party interest expense (note 10)

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense (note 9)

-

-

2,526

1,391

-

93

214

501

801

1,010

1,193

1,211

1,218

1,225

1,232

1,238

1,030

1,368

2,092

6,318

9,157

9,649

0

0

0

-

-

-

-

1,908

2,450

2,350

2,089

1,841

1,820

1,820

0

0

0

Other Nonoperating Expense

-

-

-

-

-

-

-

-

-

6,882

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment and other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

Interest and investment income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

356

310

0

0

0

Total other expense

-1,818

-1,447

-1,384

-346

595

676

443

980

-6,040

-6,105

-5,805

-6,108

687

790

313

-359

-142

-933

-1,811

-6,060

-9,026

-9,310

-8,099

-3,376

-410

896

879

278

-260

-1,156

-1,747

-1,746

-1,736

-1,514

-1,464

-1,510

0

0

0

Loss before income taxes

-44,199

-47,111

-43,949

-19,151

-15,600

-11,253

-11,050

0

0

-42,550

-

-

-

0

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Income taxes benefit

0

-54

-54

-54

-54

0

-720

0

0

-720

-

-

-

0

-

-

-

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Net Income (Loss) Attributable to Parent

-44,199

-47,057

-43,895

-19,097

-15,546

-11,253

-10,330

-30,815

-40,806

-41,830

-57,463

-69,857

88

-30,101

-46,361

15,681

-75,738

-128,376

-129,529

-68,856

-68,452

-17,416

-9,998

-147,153

-141,720

-126,780

-140,839

-88,498

-70,568

-53,964

-21,041

-51,389

-48,458

-40,042

-46,931

-40,927

0

0

0

Basic and diluted loss per common share (in dollars per share)

-0.19

-

-

-0.18

-0.24

-

-

-0.12

-0.18

-0.14

-

-0.34

-0.21

-

-0.39

-

-0.82

-

-

-

-1.91

-

-

-0.78

-0.87

-

-

-0.68

-0.57

-

-

-0.54

-0.40

-

-

-0.44

-0.09

-0.80

-0.23

Basic and diluted weighted average number of common shares outstanding (in shares)

57,343

-

-

56,942

56,924

-

-

55,966

51,883

50,721

-

50,455

50,423

-

49,583

-

49,339

-

-

-

48,939

-

-

48,543

48,348

-

-

47,915

47,620

-

-

27,061

26,776

-

-

26,567

-

-

-

Earnings Per Share, Basic

-

-

-0.20

-

-

-

0.23

-

-

-

-0.14

-

-

-

-

1.05

-

-

0.85

-0.78

-

-

2.08

-

-

-

-0.71

-

-

-

0.57

-

-

-

-0.45

-

-

-

-

Earnings Per Share, Diluted

-

-

-0.20

-

-

-

0.23

-

-

-

-0.14

-

-

-

-

1.05

-

-

0.84

-0.78

-

-

2.03

-

-

-

-0.71

-

-

-

0.52

-

-

-

-0.45

-

-

-

-

Weighted Average Number of Shares Outstanding, Basic

-

-

57,028

-

-

-

56,851

-

-

-

50,635

-

-

-

-

49,437

-

-

49,188

49,076

-

-

48,632

-

-

-

48,052

-

-

-

32,039

-

-

-

26,666

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

57,028

-

-

-

57,638

-

-

-

50,635

-

-

-

-

49,439

-

-

49,764

49,076

-

-

49,735

-

-

-

48,052

-

-

-

35,173

-

-

-

26,666

-

-

-

-

Other comprehensive loss:
Basic and diluted weighted average number of common shares outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,536

26,333

26,285

Net unrealized holding gains on available-for-sale securities arising during the period

113

16

30

26

14

11

-3

0

-11

-12

-3

-2

-40

-48

2

-101

-70

-69

-132

-59

-45

-42

-33

115

4

22

55

-19

75

112

93

24

43

-32

0

0

0

-

-

Comprehensive loss

-44,086

-47,041

-43,865

-19,071

-15,532

-11,242

-10,333

-30,815

-40,817

-41,842

-57,466

-69,859

48

-30,149

-46,359

15,580

-75,808

-128,445

-129,661

-68,915

-68,497

-17,458

-10,031

-147,038

-141,716

-126,758

-140,784

-88,517

-70,493

-53,852

-20,948

-51,365

-48,415

-40,074

0

0

0

-

-

Collaboration revenue
Total revenues

0

2,000

2,000

24,000

24,000

22,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty revenue
Total revenues

1,335

1,049

888

545

288

146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-